Leerink Partnrs Reduces Earnings Estimates for Inari Medical

Inari Medical, Inc. (NASDAQ:NARI) – Investment analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Inari Medical in a research note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the company will earn $0.02 per share for the quarter, down from their prior forecast of $0.03. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical’s FY2025 earnings at $0.18 EPS and FY2026 earnings at $0.29 EPS.

Other equities analysts have also issued reports about the stock. Robert W. Baird upped their target price on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 29th. Stifel Nicolaus initiated coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 price objective for the company. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Piper Sandler increased their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 29th. Finally, Truist Financial increased their price objective on shares of Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research note on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Inari Medical presently has an average rating of “Hold” and a consensus target price of $58.89.

Inari Medical Trading Up 0.4 %

Shares of NASDAQ NARI opened at $51.03 on Wednesday. The firm has a market cap of $2.99 billion, a PE ratio of -37.80 and a beta of 0.96. Inari Medical has a 1-year low of $36.73 and a 1-year high of $67.13. The company has a fifty day moving average price of $46.00 and a 200 day moving average price of $47.45.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NARI. GAMMA Investing LLC raised its holdings in Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after acquiring an additional 438 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after purchasing an additional 435 shares during the period. KBC Group NV increased its holdings in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after purchasing an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after purchasing an additional 522 shares during the period. Finally, Covestor Ltd increased its holdings in shares of Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock worth $99,000 after purchasing an additional 926 shares during the period. 90.98% of the stock is owned by institutional investors.

Insider Activity at Inari Medical

In other Inari Medical news, CFO Mitch C. Hill sold 3,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $45.13, for a total value of $135,390.00. Following the transaction, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at $8,105,348. This represents a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $45.83, for a total transaction of $1,833,200.00. Following the completion of the transaction, the director now directly owns 643,296 shares in the company, valued at approximately $29,482,255.68. This represents a 5.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 186,000 shares of company stock worth $8,990,990. Insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.